Thursday, October 22, 2009
Wednesday, October 21, 2009
Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
note: in 2 ovarian cancer patients (study)
Forgotten node: A case report. [World J Gastroenterol. 2009] - PubMed Result
1: World J Gastroenterol. 2009 Oct 21;15(39):4974-5.
Forgotten node: A case report.
Fratellone PM, Holowecki MA.
Fratellone Medical Associates, 47 West 57th Street 5th Floor New York, NY 10019, United States. fratmd@aol.com.
Sister Mary Joseph nodule or node refers to a palpable nodule bulging into the umbilicus and is usually a result of a malignant cancer in the pelvis or abdomen. Traditionally it has been considered a sign of ominous prognosis. Gastrointestinal malignancies, most commonly gastric, colon and pancreatic cancer account for about 52% of the underlying sources. Gynecological cancers, most commonly ovarian and uterine cancers account for about 28% of the sources.
Tuesday, October 20, 2009
Biphasic effects of hormone treatment on risk of cardiovascular disease —
"Regularly ovulating women of reproductive age are significantly protected against CVD compared with men, but CVD increases within 10 years of menopause to levels matching or exceeding incidence rates among men,13 suggesting that ovarian estrogen may help protect women against atherosclerosis. This observation led to the corollary hypothesis that treatment of postmenopausal women with estrogens (menopausal hormone therapy [MHT]) might prevent the postmenopausal increase in CVD rates. Yet, despite more than 30 years of research attempting to define whether and how postmenopausal estrogen replacement might protect women against CVD, the issue remains uncertain and, indeed, controversial...."
Monday, October 19, 2009
CBC News - Nfld. & Labrador - N.L. rate of chemo mistakes not alarming: cancer society
CBC News - Nfld. & Labrador - N.L. rate of chemo mistakes not alarming: cancer society: "A spokesperson for the Canadian Cancer Society says she isn't alarmed over revelations about the number of mistakes made during treatments in Newfoundland and Labrador."
The Director's Notes for October 16, 2009 - National Cancer Institute
"..Too often, those diagnosed with cancer hear, "The patient failed therapy," when the truth is that the therapy failed the patient.
The phrase was the subject of a 2009 commentary in The Oncologist by my colleagues Dr. Edward Benz, Jr., Director of Dana-Farber Cancer Institute in Boston, and Dr. Susan Bates from NCI's Center for Cancer Research. My hope is that in the future we will no longer need to use the word failure when it comes to treatments for cancer patients...."
Subscribe to:
Posts
(
Atom
)
